{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:47Z","timestamp":1791613667309,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["NCT05986682"],"award-info":[{"award-number":["NCT05986682"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clml.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T19:09:11Z","timestamp":1744744151000},"page":"e570-e579.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and\/or Refractory Multiple Myeloma: A Real-World Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-763X","authenticated-orcid":false,"given":"Mihir N.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-4238","authenticated-orcid":false,"given":"Susan C.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7397-8712","authenticated-orcid":false,"given":"Caroline","family":"Falvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5410-8146","authenticated-orcid":false,"given":"Jesse D.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris W.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-9050","authenticated-orcid":false,"given":"Amanda","family":"Bolgioni-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie","family":"Elcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Iadeluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Costa Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.04.008_bib0001","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0002","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.04.008_bib0003","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2025.04.008_bib0004","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with >\/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.clml.2025.04.008_bib0006","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.clml.2025.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14712598.2023.2218543","article-title":"Belantamab mafodotin in multiple myeloma","volume":"23","author":"Martino","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2025.04.008_bib0008","unstructured":"FDA approves GSK\u2019s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma [Internet]. London, UK: GlaxoSmithKline; August 6, 2020. Accessed April 1, 2024: Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma\/."},{"issue":"22","key":"10.1016\/j.clml.2025.04.008_bib0009","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.008_bib0010","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/JCO.2023.41.16_suppl.8007","volume":"41","author":"Weisel","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.008_bib0011","unstructured":"GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation [Internet]. London, UK: GlaxoSmithKline; November 22, 2022. Accessed April 1, 2024: Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/."},{"key":"10.1016\/j.clml.2025.04.008_bib0012","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.008_bib0013","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.008_bib0015","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2023-178009","article-title":"Impact of long-term treatment with Belantamab Mafodotin on safety and efficacy outcomes in patients with relapsed\/refractory multiple myeloma in DREAMM-3","volume":"142","author":"Hungria","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0016","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJMe2406799","article-title":"A Belantamab Mafodotin revival in multiple myeloma therapy","volume":"391","author":"Trudel","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.04.008_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inf"},{"issue":"7","key":"10.1016\/j.clml.2025.04.008_bib0019","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.008_bib0020","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.3390\/curroncol29070355","article-title":"Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies","volume":"29","author":"Stalker","year":"2022","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0021","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/journalofethics.2017.19.5.stas1-1705","article-title":"Assessing psychological toxicity and patient-reported distress as the sixth vital sign in cancer care and clinical trials","volume":"19","author":"LeBlanc","year":"2017","journal-title":"AMA J Ethics"},{"issue":"2","key":"10.1016\/j.clml.2025.04.008_bib0022","first-page":"175","article-title":"Use of the distress thermometer in clinical practice","volume":"10","author":"Ownby","year":"2019","journal-title":"J Adv Pr Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.04.008_bib0023","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/psp4.13016","article-title":"Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma","volume":"12","author":"Collins","year":"2023","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.008_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.18298","article-title":"Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma","volume":"199","author":"Abeykoon","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.04.008_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-world outcomes of Belantamab Mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP)","volume":"11","author":"Alegre","year":"2023","journal-title":"Oncol Ther"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.008_bib0026","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1200\/JCO.2022.40.16_suppl.8060","article-title":"Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed\/refractory multiple myeloma","volume":"40","author":"Becnel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.04.008_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112964","article-title":"Belantamab Mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain","volume":"15","author":"de la Rubia","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.008_bib0028","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2022-171077","article-title":"Belantamab Mafodotin in patients with relapsed\/refractory multiple myeloma, a real-world single center experience","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.008_bib0029","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1182\/blood-2022-164929","article-title":"Belantamab Mafodotin (Belamaf) for relapsed\/refractory multiple myeloma (RRMM): a real-world observational study","volume":"140","author":"Hultcrantz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.008_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1026251","article-title":"Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: a multicentric real-life experience","volume":"12","author":"Iula","year":"2022","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.04.008_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411829","article-title":"Real-world effectiveness and safety of Belantamab Mafodotin monotherapy in triple-class refractory multiple myeloma","volume":"24","author":"Ntanasis-Stathopoulos","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.008_bib0032","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1182\/blood-2022-166399","article-title":"Belantamab Mafodotin in patients with relapsed and refractory multiple myeloma who have received at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody: a retro-prospective Italian observational study","volume":"140","author":"Offidani","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.008_bib0033","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study","volume":"200","author":"Shragai","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2025.04.008_bib0034","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.3324\/haematol.2022.281772","article-title":"Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study","volume":"108","author":"Talbot","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.04.008_bib0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"Real-life\" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.008_bib0036","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2022-156035","article-title":"Effectiveness and safety of Belantamab Mafodotin in patients with relapsed or refractory multiple myeloma in real-life setting: the ALFA study","volume":"140","author":"Roussel","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.04.008_bib0037","first-page":"467","article-title":"Symptom burden and its functional impact in patients with ``symptomatic'' relapsed or refractory multiple myeloma","volume":"29","author":"Kamal","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2025.04.008_bib0038","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.04.008_bib0039","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.008_bib0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.04.008_bib0041","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ejh.13843","article-title":"Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma","volume":"109","author":"McInturf","year":"2022","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:17Z","timestamp":1762600637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2152265025001387"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and\/or Refractory Multiple Myeloma: A Real-World Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}